DNA Repair Deficiencies and the Promise of PARP Inhibition in Prostate Cancer: Clinical Implications

Register now for this CME-certified satellite symposium at AUA 2018 where you can gain expert guidance from Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD; William B. Isaacs, PhD; and Todd M. Morgan, MD, on PARP inhibitors in the treatment of advanced prostate cancer.

Interact with the experts as they discuss repair deficiencies in prostate cancer, practical challenges associated with genetic testing, and available clinical data on PARP inhibitors in advanced prostate cancer and how these agents may affect management strategies for patients in the near future.


5:30 PM - 6:00 PM Dinner and Registration

6:00 PM - 6:10 PM Welcome and Introduction

6:10 PM - 6:30 PM Overview of DNA Repair Mechanisms and the Molecular Landscape of Advanced Prostate CancerWilliam B. Isaacs, PhD

6:30 PM - 6:50 PM The Intersection of Germline and Somatic Genetic Testing in Advanced Prostate CancerTodd M. Morgan, MD

6:50 PM - 7:30 PM DNA Repair Defects as a Therapeutic Target in Advanced Prostate Cancer: The Role of PARP InhibitorsJohann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD (Program Director)

7:30 PM - 8:00 PM Challenges Moving Forward: Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD

Professor of Experimental Cancer Medicine
Department of Medicine and Drug Development
Institute of Cancer Research
Honorary Consultant Medical Oncology
Department of Medicine and Drug Development
Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, United Kingdom

William B. Isaacs, PhD

Department of Urology
Johns Hopkins School of Medicine
Baltimore, Maryland

Todd M. Morgan, MD

Associate Professor
Department of Urology
University of Michigan
Ann Arbor, Michigan

Goal Statement
The goal of this activity is to improve participants’ knowledge of BRCA and other DNA repair gene testing as well as competence in applying the latest data on PARP inhibitors to optimize the treatment of patients with prostate cancer.

Target Audience
This program is intended for urologists and other healthcare providers who care for patients with prostate cancer.

Learning Objectives

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or ATM mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents or therapies in prostate cancer


Physicians Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.